Argenica boosts cash reserves with $3.97m R&D rebate to advance stroke drug

The latest update is out from Argenica Therapeutics Ltd ( (AU:AGN) ).

Argenica Therapeutics has received a $3.97 million cash rebate under the Australian Federal Government’s R&D Tax Incentive Program for eligible research and development activities conducted in the 2025 financial year, including newly approved overseas work. Following this rebate, the company reported a pro forma cash balance of $9 million as at 31 December 2025, strengthening its financial position.

The additional funding will be directed towards advancing preparatory activities for a targeted Phase 2b acute ischaemic stroke trial of its lead neuroprotective peptide ARG-007, in consultation with its global stroke Clinical Advisory Group and potential pharmaceutical partners. This bolstered cash runway supports ongoing clinical and preclinical development, potentially enhancing Argenica’s positioning in the stroke and brain-injury therapeutics market and providing greater visibility for stakeholders on the company’s near-term development plans.

The most recent analyst rating on (AU:AGN) stock is a Sell with a A$0.19 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Limited is an Australian biotechnology company focused on developing novel neuroprotective therapeutics to reduce brain tissue death following stroke, traumatic brain injury, hypoxic ischaemic encephalopathy and other neurodegenerative conditions. Its lead candidate, ARG-007, a neuroprotective peptide, has shown efficacy in pre-clinical models, completed a Phase 1 safety trial in healthy volunteers and has now entered a Phase 2 clinical trial in acute ischaemic stroke patients.

Average Trading Volume: 188,829

Technical Sentiment Signal: Sell

Current Market Cap: A$28.26M

For an in-depth examination of AGN stock, go to TipRanks’ Overview page.